Lu Lu

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3475176/lu-lu-publications-by-year.pdf
Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

215 papers	8,463 citations	42 h-index	86 g-index
240 ext. papers	11,507 ext. citations	10.8 avg, IF	6.56 L-index

#	Paper	IF	Citations
215	A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs.. *Cell Research*, **2022**,	24.7	10
214	Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine.. *Emerging Microbes and Infections*, **2022**, 1-17	18.9	9
213	Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron.. *Nature*, **2022**,	50.4	70
212	A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells.. *MBio*, **2022**, e0338421	7.8	0
211	Dissolving microneedle-encapsulated drug-loaded nanoparticles and recombinant humanized collagen type III for the treatment of chronic wound anti-inflammation and enhanced cell proliferation and angiogenesis.. *Nanoscale*, **2022**,	7.7	3
210	Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.. *Cell Research*, **2022**,	24.7	6
209	Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants.. *Vaccines*, **2022**, 10,	5.3	1
208	Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant.. *Vaccines*, **2022**, 10,	5.3	4
207	Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in mouse model.. *Emerging Microbes and Infections*, **2022**, 1-36	18.9	1
206	Microfibrillated cellulose-enhanced carboxymethyl chitosan/oxidized starch sponge for chronic diabetic wound repair.. *Materials Science and Engineering C*, **2022**, 112669	8.3	1
205	A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant.. *Cell Research*, **2022**,	24.7	2
204	Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.. *MSphere*, **2022**, e0091521	5	0
203	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.. *Cell*, **2022**,	56.2	6
202	A genome-scale screen for synthetic drivers of T cell proliferation.. *Nature*, **2022**, 603, 728-735	50.4	3
201	Interferon-gamma inhibits influenza A virus cellular attachment by reducing sialic acid cluster size.. *IScience*, **2022**, 25, 104037	6.1	2
200	Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.. *EBioMedicine*, **2022**, 79, 103986	8.8	3
199	Design of artificial α-helical peptides targeting both gp41 deep pocket and subpocket as potent HIV-1 fusion inhibitors.. *European Journal of Medicinal Chemistry*, **2022**, 236, 114336	6.8	

198	Injectable multifunctional hyaluronic acid/methylcellulose hydrogels for chronic wounds repairing.. *Carbohydrate Polymers*, **2022**, 289, 119456	10.3	3
197	Coronavirus Entry Inhibitors.. *Advances in Experimental Medicine and Biology*, **2022**, 1366, 101-121	3.6	1
196	Long-acting Protective Ocular Surface by Instilling Adhesive Dual-antiviral Nanoparticles.. *Advanced Healthcare Materials*, **2022**, e2200283	10.1	1
195	SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with delta variant in TMPRSS2-expressed cells.. *Emerging Microbes and Infections*, **2021**, 1-18	18.9	75
194	Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients.. *Clinical Infectious Diseases*, **2021**,	11.6	94
193	Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant.. *Vaccines*, **2021**, 9,	5.3	8
192	Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha). *Cell Discovery*, **2021**, 7, 109	22.3	8
191	A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. *Signal Transduction and Targeted Therapy*, **2021**, 6, 378	21	5
190	Correlation between Commercial Anti-RBD IgG Titer and Neutralization Titer against SARS-CoV-2 Beta Variant.. *Diagnostics*, **2021**, 11,	3.8	2
189	Microenvironment-responsive multifunctional hydrogels with spatiotemporal sequential release of tailored recombinant human collagen type III for the rapid repair of infected chronic diabetic wounds. *Journal of Materials Chemistry B*, **2021**, 9, 9684-9699	7.3	5
188	High compliance to infection control measures prevented guest-to-staff transmission in COVID-19 quarantine hotels. *Journal of Infection*, **2021**,	18.9	1
187	Emerging SARS-CoV-2 variants expand species tropism to murines. *EBioMedicine*, **2021**, 73, 103643	8.8	34
186	25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
185	Antivirals with common targets against highly pathogenic viruses. *Cell*, **2021**, 184, 1604-1620	56.2	24
184	The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2. *Signal Transduction and Targeted Therapy*, **2021**, 6, 132	21	17
183	Immunoengineered adjuvants for universal vaccines against respiratory viruses. *Fundamental Research*, **2021**, 1, 189-192		1
182	Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection. *Molecules*, **2021**, 26,	4.8	3
181	Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human Coronavirus Infection. *Journal of Medicinal Chemistry*, **2021**,	8.3	1

180	Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection. *Microbes and Infection* , **2021**, 23, 104840	9.3	1
179	A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses. *Cell and Bioscience*, **2021**, 11, 128	9.8	2
178	A "Two-Birds-One-Stone" Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region. *Journal of Medicinal Chemistry*, **2021**, 64, 11460-11471	8.3	2
177	Engineered trimeric ACE2 binds viral spike protein and locks it in "Three-up" conformation to potently inhibit SARS-CoV-2 infection. *Cell Research*, **2021**, 31, 98-100	24.7	35
176	Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells. *Cell*, **2021**, 184, 92-105.e16	36.2	240
175	Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. *Nature Communications*, **2021**, 12, 866	17.4	40
174	Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. *Cell Reports*, **2021**, 34, 108699	10.6	54
173	Impact of SARS-CoV-2 variant-associated RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination. *Clinical Infectious Diseases*, **2021**,	11.6	28
172	Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. *Signal Transduction and Targeted Therapy*, **2021**, 6, 288	21	13
171	Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation. *Signal Transduction and Targeted Therapy*, **2021**, 6, 318	21	2
170	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. *Acta Pharmaceutica Sinica B*, **2021**,	15.5	4
169	The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum. *EBioMedicine*, **2021**, 71, 103544	8.8	16
168	An ultrapotent pan-□coronavirus lineage B (□CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. *Protein and Cell*, **2021**, 1	7.2	2
167	A tailored extracellular matrix (ECM) - Mimetic coating for cardiovascular stents by stepwise assembly of hyaluronic acid and recombinant human type III collagen. *Biomaterials*, **2021**, 276, 121055	15.6	14
166	Inhibition of viral suppressor of RNAi proteins by designer peptides protects from enteroviral infection in□vivo. *Immunity*, **2021**, 54, 2231-2244.e6	32.3	7
165	AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. *Cell Research*, **2021**, 31, 126-140	24.7	165
164	Pan-coronavirus fusion inhibitors as the hope for today and tomorrow. *Protein and Cell*, **2021**, 12, 84-88	7.2	14
163	Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine. *Vaccines*, **2020**, 8,	5.3	2

162	Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells. *Frontiers in Microbiology*, **2020**, 11, 1063	5.7	19
161	Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study. *Lancet Microbe, The*, **2020**, 1, e111-e118	22.2	56
160	Identification of Human Single-Domain Antibodies against SARS-CoV-2. *Cell Host and Microbe*, **2020**, 27, 891-898.e5	23.4	155
159	The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. *Signal Transduction and Targeted Therapy*, **2020**, 5, 92	21	170
158	An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells. *Science Translational Medicine*, **2020**, 12,	17.5	5
157	Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	23
156	Development of oncolytic virotherapy: from genetic modification to combination therapy. *Frontiers of Medicine*, **2020**, 14, 160-184	12	13
155	Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. *Cell Research*, **2020**, 30, 343-355	24.7	745
154	Sodium Copper Chlorophyllin Is Highly Effective against Enterovirus (EV) A71 Infection by Blocking Its Entry into the Host Cell. *ACS Infectious Diseases*, **2020**, 6, 882-890	5.5	6
153	High neutralizing antibody titer in intensive care unit patients with COVID-19. *Emerging Microbes and Infections*, **2020**, 9, 1664-1670	18.9	86
152	Design, modeling and 3D printing of a personalized cervix tissue implant with protein release function. *Biomedical Materials (Bristol)*, **2020**, 15, 045005	3.5	5
151	Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. *Emerging Microbes and Infections*, **2020**, 9, 382-385	18.9	862
150	Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity. *Science*, **2020**, 367,	33.3	105
149	Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. *Cellular and Molecular Immunology*, **2020**, 17, 765-767	15.4	382
148	Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection. *Virologica Sinica*, **2020**, 35, 340-343	6.4	8
147	A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome. *Cellular and Molecular Immunology*, **2020**, 17, 554	15.4	91
146	Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit. *Virologica Sinica*, **2020**, 35, 857-860	6.4	17
145	Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 27141-27147	11.5	91

144	Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. *Cellular and Molecular Immunology*, **2020**, 17, 894	15.4	56
143	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. *Signal Transduction and Targeted Therapy*, **2020**, 5, 282	21	71
142	Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. *JAMA Internal Medicine*, **2020**, 180, 1356-1362	11.5	152
141	Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1. *Frontiers in Pharmacology*, **2020**, 11, 613361	5.6	3
140	Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41. *Viruses*, **2019**, 11,	6.2	20
139	Design and Biological Evaluation of -Xylene Thioether-Stapled Short Helical Peptides Targeting the HIV-1 gp41 Hexameric Coiled-Coil Fusion Complex. *Journal of Medicinal Chemistry*, **2019**, 62, 8773-8783	8.3	4
138	Assessment of population susceptibility to upcoming seasonal influenza epidemic strain using interepidemic emerging influenza virus strains. *Epidemiology and Infection*, **2019**, 147, e279	4.3	6
137	A Novel CXCR4 Targeting Protein SDF-1/54 as an HIV-1 Entry Inhibitor. *Viruses*, **2019**, 11,	6.2	3
136	Sin1/mTORC2 regulate B cell growth and metabolism by activating mTORC1 and Myc. *Cellular and Molecular Immunology*, **2019**, 16, 757-769	15.4	9
135	Dlg1 Maintains Dendritic Cell Function by Securing Voltage-Gated K Channel Integrity. *Journal of Immunology*, **2019**, 202, 3187-3197	5.3	6
134	A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life. *Molecules*, **2019**, 24,	4.8	14
133	A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. *Science Advances*, **2019**, 5, eaav4580	14.3	268
132	Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. *Journal of Virology*, **2019**, 93,	6.6	4
131	A Peptide-Based Virus Inactivator Protects Male Mice Against Zika Virus-Induced Damage of Testicular Tissue. *Frontiers in Microbiology*, **2019**, 10, 2250	5.7	5
130	Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator. *Viruses*, **2019**, 11,	6.2	6
129	Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41. *Aids*, **2019**, 33, 1545-1555	3.5	12
128	IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. *PLoS Pathogens*, **2019**, 15, e1008082	7.6	7
127	Characterization by high-resolution crystal structure analysis of a triple-helix region of human collagen type III with potent cell adhesion activity. *Biochemical and Biophysical Research Communications*, **2019**, 508, 1018-1023	3.4	17

126	Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4. *Viruses*, **2019**, 11,	6.2	20
125	Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD. *Viruses*, **2019**, 11,	6.2	14
124	Rhinovirus respiratory tract infection in hospitalized adult patients is associated with T2 response irrespective of asthma. *Journal of Infection*, **2018**, 76, 465-474	18.9	7
123	A CCR5 antagonist-based HIV entry inhibitor exhibited potent spermicidal activity: Potential application for contraception and prevention of HIV sexual transmission. *European Journal of Pharmaceutical Sciences*, **2018**, 117, 313-320	5.1	7
122	The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects. *Protein and Cell*, **2018**, 9, 596-615	7.2	26
121	AXL promotes Zika virus infection in astrocytes by antagonizing type I interferon signalling. *Nature Microbiology*, **2018**, 3, 302-309	26.6	92
120	Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	46
119	Intra-amniotic Injection of Mouse Embryos. *Bio-protocol*, **2018**, 8, e2854	0.9	
118	Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus. *Microbes and Infection*, **2018**, 20, 626-634	9.3	14
117	Topical Application of a Vitamin A Derivative and Its Combination With Non-ablative Fractional Laser Potentiates Cutaneous Influenza Vaccination. *Frontiers in Microbiology*, **2018**, 9, 2570	5.7	5
116	The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses. *Frontiers in Microbiology*, **2018**, 9, 2643	5.7	18
115	A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells. *Aids*, **2018**, 32, 1749-1761	3.5	8
114	Enhancement of endocytic uptake of HIV-1 virions into CD4-negative epithelial cells by HIV-1 gp41 via its interaction with POB1. *Cellular and Molecular Immunology*, **2017**, 14, 568-571	15.4	2
113	Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015). *Expert Opinion on Therapeutic Patents*, **2017**, 27, 707-719	6.8	19
112	Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	15
111	Additional molecular testing of saliva specimens improves the detection of respiratory viruses. *Emerging Microbes and Infections*, **2017**, 6, e49	18.9	73
110	HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions. *Emerging Microbes and Infections*, **2017**, 6, e59	18.9	17
109	A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity. *Aids*, **2017**, 31, 885-894	3.5	24

108	Visual and Motor Deficits in Grown-up Mice with Congenital Zika Virus Infection. *EBioMedicine*, **2017**, 20, 193-201	8.8	40
107	Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains. *Journal of Infection*, **2017**, 75, 68-71	18.9	6
106	MERS-CoV spike protein: a key target for antivirals. *Expert Opinion on Therapeutic Targets*, **2017**, 21, 131-143	6.4	176
105	A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. *Cell Host and Microbe*, **2017**, 22, 471-483.e5	23.4	36
104	Zika virus infects renal proximal tubular epithelial cells with prolonged persistency and cytopathic effects. *Emerging Microbes and Infections*, **2017**, 6, e77	18.9	26
103	Genomic signature analysis of the recently emerged highly pathogenic A(H5N8) avian influenza virus: implying an evolutionary trend for bird-to-human transmission. *Microbes and Infection*, **2017**, 19, 597-604	9.3	10
102	A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses. *Nature Communications*, **2017**, 8, 15672	17.4	83
101	HIV-1 Env DNA prime plus gp120 and gp70-V1V2 boosts induce high level of V1V2-specific IgG and ADCC responses and low level of Env-specific IgA response: implication for improving RV144 vaccine regimen. *Emerging Microbes and Infections*, **2017**, 6, e102	18.9	2
100	Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses. *Frontiers of Medicine*, **2017**, 11, 449-461	12	16
99	Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors. *Journal of Virology*, **2017**, 91,	6.6	23
98	Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. *Emerging Microbes and Infections*, **2017**, 6, e89	18.9	33
97	Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile. *Molecules*, **2017**, 22,	4.8	11
96	Advancements in Developing Strategies for Sterilizing and Functional HIV Cures. *BioMed Research International*, **2017**, 2017, 6096134	3	23
95	Poly(U) and CpG ameliorate the unbalanced T cell immunity and pneumonia of mice with RSV vaccine-enhanced disease. *BioScience Trends*, **2017**, 11, 450-459	9.9	2
94	Normal human sera contain heat-sensitive factor(s) to enhance H7N9 influenza virus infection. *Journal of Infection*, **2016**, 72, 123-5	18.9	
93	Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. *Journal of Virology*, **2016**, 90, 57-67	6.6	64
92	A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41. *Amino Acids*, **2016**, 48, 2867-2873	3.5	7
91	Rational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations. *Scientific Reports*, **2016**, 6, 31983	4.9	11

90	Site-specific Isopeptide Bridge Tethering of Chimeric gp41 N-terminal Heptad Repeat Helical Trimers for the Treatment of HIV-1 Infection. *Scientific Reports*, **2016**, 6, 32161	4.9	8
89	Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. *Cellular and Molecular Immunology*, **2016**, 13, 180-90	15.4	96
88	An effective strategy for recapitulating N-terminal heptad repeat trimers in enveloped virus surface glycoproteins for therapeutic applications. *Chemical Science*, **2016**, 7, 2145-2150	9.4	5
87	Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41. *Current Topics in Medicinal Chemistry*, **2016**, 16, 1074-90	3	49
86	Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles: cocktail therapeutic strategy for antiviral therapy. *Aids*, **2016**, 30, 827-38	3.5	24
85	An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene. *Emerging Microbes and Infections*, **2016**, 5, e65	18.9	22
84	Safety evaluation of chemically modified beta-lactoglobulin administered intravaginally. *Journal of Medical Virology*, **2016**, 88, 1098-101	19.7	6
83	A randomized open-label clinical trial of an anti-HPV biological dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection. *Microbes and Infection*, **2016**, 18, 148-52	9.3	10
82	Intranasal application of polyethyleneimine suppresses influenza virus infection in mice. *Emerging Microbes and Infections*, **2016**, 5, e41	18.9	7
81	Adenovirus-based vaccines against avian-origin H5N1 influenza viruses. *Microbes and Infection*, **2015**, 17, 135-41	9.3	5
80	Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS). *Emerging Microbes and Infections*, **2015**, 4, e37	18.9	9
79	Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection. *Journal of Infectious Diseases*, **2015**, 212, 1894-903	7	71
78	Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infection. *Viruses*, **2015**, 7, 798-819	6.2	6
77	Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy. *Journal of Virology*, **2015**, 89, 6960-4	6.6	15
76	Intranasally administered peptidic viral fusion inhibitor protected hDPP4 transgenic mice from MERS-CoV infection. *Lancet, The*, **2015**, 386, S44	40	3
75	An artificial peptide-based HIV-1 fusion inhibitor containing M-T hook structure exhibiting improved antiviral potency and drug resistance profile. *Future Virology*, **2015**, 10, 961-969	2.4	
74	ADS-J1 inhibits semen-derived amyloid fibril formation and blocks fibril-mediated enhancement of HIV-1 infection. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 5123-34	5.9	15
73	design of isopeptide bond-tethered triple-stranded coiled coils with exceptional resistance to unfolding and proteolysis: implication for developing antiviral therapeutics. *Chemical Science*, **2015**, 6, 6505-6509	9.4	8

72	Advancements in the development of subunit influenza vaccines. *Microbes and Infection*, **2015**, 17, 123-34	9.3	30
71	Development of therapeutics for treatment of Ebola virus infection. *Microbes and Infection*, **2015**, 17, 109-17	9.3	34
70	Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 742-4	5.9	33
69	Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy. *Scientific Reports*, **2015**, 5, 13028	4.9	25
68	Alterations in serotonin, transient receptor potential channels and protease-activated receptors in rats with irritable bowel syndrome attenuated by Shugan decoction. *World Journal of Gastroenterology*, **2015**, 21, 4852-63	5.6	19
67	Receptor binding domain based HIV vaccines. *BioMed Research International*, **2015**, 2015, 594109	3	4
66	Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. *Microbes and Infection*, **2015**, 17, 142-8	9.3	28
65	Receptor-binding domain-based subunit vaccines against MERS-CoV. *Virus Research*, **2015**, 202, 151-9	6.4	49
64	A nanoparticle-encapsulated non-nucleoside reverse-transcriptase inhibitor with enhanced anti-HIV-1 activity and prolonged circulation time in plasma. *Current Pharmaceutical Design*, **2015**, 21, 925-35	3.3	14
63	Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. *Journal of Virology*, **2014**, 88, 7796-805	6.6	182
62	Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. *Nature Communications*, **2014**, 5, 3067	17.4	247
61	ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer. *Biochimica Et Biophysica Acta - Biomembranes*, **2014**, 1838, 1296-305	3.8	22
60	Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. *Virus Research*, **2014**, 194, 200-10	6.4	79
59	Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 1537-45	5.1	12
58	Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics. *Journal of Medicinal Chemistry*, **2014**, 57, 7342-54	8.3	29
57	Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 3719-23	2.9	6
56	Peptides derived from HIV-1 gp120 co-receptor binding domain form amyloid fibrils and enhance HIV-1 infection. *FEBS Letters*, **2014**, 588, 1515-22	3.8	17
55	HIV-1 impairs human retinal pigment epithelial barrier function: possible association with the pathogenesis of HIV-associated retinopathy. *Laboratory Investigation*, **2014**, 94, 777-87	5.9	19

54	Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity. *Aids*, **2014**, 28, 1251-60	3.5	13
53	Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2014**, 67, 1-6	3.1	22
52	Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China. *Virology Journal*, **2013**, 10, 10	6.1	13
51	Putative conformations of the receptor-binding domain in S protein of hCoV-EMC in complex with its receptor dipeptidyl peptidase-4. *Journal of Infection*, **2013**, 67, 156-8	18.9	6
50	An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 2533-44	5.1	29
49	Chemically modified bovine beta-lactoglobulin inhibits human papillomavirus infection. *Microbes and Infection*, **2013**, 15, 506-10	9.3	15
48	F(ab')2 fragment of a gp41 NHR-trimer-induced IgM monoclonal antibody neutralizes HIV-1 infection and blocks viral fusion by targeting the conserved gp41 pocket. *Microbes and Infection*, **2013**, 15, 887-94	9.3	3
47	PA-356R is a unique signature of the avian influenza A (H7N9) viruses with bird-to-human transmissibility: potential implication for animal surveillances. *Journal of Infection*, **2013**, 67, 490-4	18.9	17
46	A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. *Journal of Infection*, **2013**, 66, 464-6	18.9	34
45	Design, synthesis, and biological evaluation of highly potent small molecule-peptide conjugates as new HIV-1 fusion inhibitors. *Journal of Medicinal Chemistry*, **2013**, 56, 2527-39	8.3	20
44	Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 7539-48	3.4	23
43	Genomic signature and protein sequence analysis of a novel influenza A (H7N9) virus that causes an outbreak in humans in China. *Microbes and Infection*, **2013**, 15, 432-9	9.3	67
42	Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. *Microbes and Infection*, **2013**, 15, 625-9	9.3	59
41	Highly pathogenic avian influenza A(H5N1) mutants transmissible by air are susceptible to human and animal neutralizing antibodies. *Journal of Infectious Diseases*, **2013**, 208, 1315-9	7	5
40	Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket. *Viruses*, **2013**, 5, 127-49	6.2	39
39	Respiratory syncytial virus entry inhibitors targeting the F protein. *Viruses*, **2013**, 5, 211-25	6.2	52
38	Serological investigation of subclinical influenza A(H7H9) infection among healthcare and non-healthcare workers in Zhejiang Province, China. *Clinical Infectious Diseases*, **2013**, 57, 919-21	11.6	14
37	Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. *Journal of Virology*, **2013**, 87, 9939-42	6.6	140

36	3-Hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate inhibits HIV infection by blocking viral entry. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 573-6	5.1	9
35	Polyanionic candidate microbicides accelerate the formation of semen-derived amyloid fibrils to enhance HIV-1 infection. *PLoS ONE*, **2013**, 8, e59777	3.7	30
34	Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure. *PLoS ONE*, **2013**, 8, e66156	3.7	6
33	Receptor-binding domain as a target for developing SARS vaccines. *Journal of Thoracic Disease*, **2013**, 5 Suppl 2, S142-8	2.6	41
32	Tactics used by HIV-1 to evade host innate, adaptive, and intrinsic immunities. *Chinese Medical Journal*, **2013**, 126, 2374-9	2.9	3
31	Design, synthesis, and biological activity of novel 1,4-disubstituted piperidine/piperazine derivatives as CCR5 antagonist-based HIV-1 entry inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 3284-6	2.9	17
30	Design of highly potent HIV fusion inhibitors based on artificial peptide sequences. *Chemical Communications*, **2012**, 48, 11579-81	5.8	14
29	A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains. *Retrovirology*, **2012**, 9, 104	3.6	49
28	HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain. *Biochimica Et Biophysica Acta - Biomembranes*, **2012**, 1818, 2950-7	3.8	26
27	Biosecurity and biosafety in research on emerging pathogens. *Emerging Microbes and Infections*, **2012**, 1, e44	18.9	4
26	Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. *Emerging Microbes and Infections*, **2012**, 1, e13	18.9	33
25	Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket. *Journal of Virology*, **2012**, 86, 589-93	6.6	21
24	The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. *PLoS ONE*, **2012**, 7, e37019	3.7	26
23	The conserved residue Arg46 in the N-terminal heptad repeat domain of HIV-1 gp41 is critical for viral fusion and entry. *PLoS ONE*, **2012**, 7, e44874	3.7	5
22	Design, synthesis, and biological activity of novel 5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41. *Journal of Medicinal Chemistry*, **2011**, 54, 572-9	8.3	63
21	HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies. *PLoS ONE*, **2011**, 6, e18233	3.7	30
20	In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor. *Journal of Biological Chemistry*, **2011**, 286, 3277-87	5.4	41
19	A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability. *Journal of Biological Chemistry*, **2011**, 286, 28425-34	5.4	13

18	HIV-1 glycoprotein 41 ectodomain induces activation of the CD74 protein-mediated extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to enhance viral infection. *Journal of Biological Chemistry*, **2011**, 286, 44869-77	5.4	7
17	Combinations of 3-hydroxyphthalic anhydride-modified ovalbumin with antiretroviral drug-based microbicide candidates display synergistic and complementary effects against HIV-1 infection. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2011**, 56, 384-92	3.1	9
16	Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides. *Journal of Biological Chemistry*, **2010**, 285, 25506-15	5.4	43
15	Identification of a gp41 core-binding molecule with homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor. *Journal of Virology*, **2010**, 84, 9359-68	6.6	16
14	Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission. *Retrovirology*, **2010**, 7, 37	3.6	20
13	The interaction between the membrane-proximal external region and the N-trimer region of HIV-1 gp41: Involvement in viral fusion. *Science Bulletin*, **2009**, 54, 1707-1712	10.6	
12	The cytoplasmic domain of influenza M2 protein interacts with caveolin-1. *Archives of Biochemistry and Biophysics*, **2009**, 486, 150-4	4.1	12
11	Using gene expression databases for classical trait QTL candidate gene discovery in the BXD recombinant inbred genetic reference population: mouse forebrain weight. *BMC Genomics*, **2008**, 9, 444	4.5	23
10	V3 CTL epitope density in a single recombinant molecule antigen differentially affects the number and activity of primary and memory CD8+ T cells. *Vaccine*, **2008**, 26, 845-52	4.1	7
9	Surface exposure of the HIV-1 env cytoplasmic tail LLP2 domain during the membrane fusion process: interaction with gp41 fusion core. *Journal of Biological Chemistry*, **2008**, 283, 16723-31	5.4	37
8	Important changes in biochemical properties and function of mutated LLP12 domain of HIV-1 gp41. *Chemical Biology and Drug Design*, **2007**, 70, 311-8	2.9	9
7	Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of caveolin-1. *Journal of Biological Chemistry*, **2007**, 282, 6143-52	5.4	39
6	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody		2
5	Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion		4
4	Fully human single-domain antibodies against SARS-CoV-2		10
3	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications		282
2	Engineered Trimeric ACE2 Binds and Locks Three-up Spike Protein to Potently Inhibit SARS-CoVs and Mutants		2
1	Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis		19